Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

This 52 week randomized, controlled trial evaluated the safety and efficacy of bempedoic acid in reducing LDL cholesterol levels among patients with hypercholesterolemia receiving maximally tolerated statin therapy. The study involved 2230 patients, with 1488 assigned to bempedoic acid and 742 to placebo. Results showed that bempedoic acid significantly reduced LDL cholesterol levels by 16.5% from baseline at week 12, with no substantial difference in overall adverse events compared to placebo. However, discontinuation rates due to adverse events and incidents of gout were higher in the bempedoic acid group. The findings support the use of bempedoic acid as an adjunct to statin therapy for LDL cholesterol reduction, with an acceptable safety profile.

This 52 week randomized, controlled trial evaluated the safety and efficacy of bempedoic acid in reducing LDL cholesterol levels among patients with hypercholesterolemia receiving maximally tolerated statin therapy. The study involved 2230 patients, with 1488 assigned to bempedoic acid and 742 to placebo. Results showed that bempedoic acid significantly reduced LDL cholesterol levels by 16.5% from baseline at week 12, with no substantial difference in overall adverse events compared to placebo. However, discontinuation rates due to adverse events and incidents of gout were higher in the bempedoic acid group. The findings support the use of bempedoic acid as an adjunct to statin therapy for LDL cholesterol reduction, with an acceptable safety profile.